New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 412
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries Appendix F Technical Notes Every effort has been made to ensure that all calculations in the report are correct; however, it is possible in a document of this length and complexity that a typographical or other error may have escaped detection. The calculations described in Chapters 4, 7, and 9 were conducted using the MULTIPLAN© spread sheet program, Version 1 (Microsoft Corporation, 10700 Northup Way, Bellevue, WA 98004), run on an IBM Personal Computer (International Business Machines, Boca Raton, FL 33432). The program requires 64K of memory. Inquiries regarding templates for these calculations for use with the MULTIPLAN© program should be directed to Director Division of Health Promotion and Disease Prevention Institute of Medicine National Academy of Sciences 2101 Constitution Avenue, N.W. Washington, D.C. 20418. Use of the MULTIPLAN© program or the IBM Personal Computer do not constitute endorsement by the Institute of Medicine or the National Academy of Sciences. © Microsoft Corporation, Bellevue, Wash.

Table of Contents

Front Matter R1-R16

1. Summary 1-18

2. Priority Setting for Health-Related Investments: A Review of Methods 19-29

3. Overview of the Analytic Approach 30-43

4. Comparison of Disease Burdens 44-62

5. Predictions of Vaccine Development 63-75

6. Assessing the Likely Utilization of New Vaccines 76-81

7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines 82-105

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 106-120

9. Findings, Conclusions, and Recommendations 121-142

Appendix A: Selection of Vaccine Candidates for Accelerated Development 143-148

Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness 149-158

Appendix C: The Burden of Disease Resulting from Diarrhea 159-169

Appendix D-1: The Prospects for Immunizing Against Dengue Virus 170-177

Appendix D-2: The Prospects for Immunizing Against Escherichia coli 178-185

Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b 186-196

Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus 197-207

Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus 208-222

Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus 223-240

Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae 241-250

Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis 251-266

Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses 267-274

Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. 275-286

Appendix D-11: The Prospects for Immunizing Against Rabies Virus 287-298

Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus 299-307

Appendix D-13: The Prospects for Immunizing Against Rotavirus 308-318

Appendix D-14: The Prospects for Immunizing Against Salmonella typhi 319-328

Appendix D-15: The Prospects for Immunizing Against Shigella spp. 329-337

Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A 338-356

Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae 357-375

Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae 376-389

Appendix D-19: The Prospects for Immunizing Against Yellow Fever 390-402

Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 403-411

Appendix F: Technical Notes 412-412

Appendix G: Biographical Notes on Committee Members 413-417

Appendix H: Additional Sources of Advice to the Committee 418-419

Appendix I: Contents of Supplement to Volume II 420-420

Appendix J: Preface to Volume I 421-422

Appendix K: Contents to Volume I 423-423

Index 424-432

Appendix F Technical Notes

Appendix F
Technical Notes